Modern approaches to the treatment of radioiodine-refractory differentiated thyroid cancer-Reference-Cited by-同舟云学术

Modern approaches to the treatment of radioiodine-refractory differentiated thyroid cancer

Published:2021 Issue:1 Volume:12 Page:35-48
ISSN:2707-0700
Container-title:Radiation Diagnostics, Radiation Therapy
language:
Short-container-title:RDRT

Author:

Dzhuzha D.¹,Myasoyedov S.²^ORCID

Affiliation:

1. National Cancer Institute, Ministry of Health of Ukraine, Kyiv

2. P.L. Shupyk National University of Healthcare of Ukraine, Kiev

Abstract

Radioiodine therapy is the main post-operation method of treatment of advanced differentiated thyroid cancer, but the loss of ability of iodine uptake causes the poor prognosis. The follow-up of patients with radioiodine-refractory differentiated thyroid cancer (RRDTC) is a serious problem. In review the definition, genesis, diagnostics and treatment of RRDTC were revealed. Taking into account the ineffectiveness of traditional methods of redifferentiation therapy, the perspectives of administration of targeted therapies with tyrosine kinase inhibitors were showed. Key words: radioiodine-refractory differentiated thyroid cancer, radioiodine therapy, targeted therapies with tyrosine kinase inhibitors.

Publisher

Institute of Nuclear Medicine and Diagnostic Radiology of the National Academy of Medical Sciences of Ukraine

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference85 articles.

1. Rumyantsev P.O. Refractoriness of highly differentiated thyroid cancer to treatment with radioactive iodine / P.O. Rumyantsev // Head and Neck Tumors. – 2013. – № 3. ¬¬– P. 11-15. http://doi.org/10.17650/2222-1468-2013-0-3-11-15.

2. A effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial / M. S. Brose, F. P. Worden, K. L. Newbold [et al.] // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. – 2017. – Vol. 35. – P. 2692–2699. http://doi.org/10.1200/JCO.2016.71.6472.

3. A phase 3 (COSMIC-311) randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy / M. S. Brose, B. Robinson, C. Bermingham [et al.] // J. Clin. Oncol. – 2019. – Vol. 37. – P. TPS6097.

4. A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC / J. Chen, Q. Ji, J. Cao [et al.] // JCO. –2017. – Vol. 35, № 15, suppl. – P. 6037. http://doi.org/10.1200/JCO.2017.35.15 suppl.6037.

5. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer / S. C. Short, A. Suovuori, G. Cook [et al.] // Clin. Oncol. (R. Coll. Radiol.). – 2004. – Vol. 16. – P. 569–574. http://doi.org/10.1016/j.clon.200.4.06.018.